On Friday April 12, 2024, the Oncologic Drugs Advisory Committee (ODAC) will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.
Back to All Events
Earlier Event: March 15
Oncologic Drugs Advisory Committee
Later Event: May 9
Blood Products Advisory Committee